News & events

Upcoming events

See all upcoming events

Latest news

Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only

Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 181 in human plasma within just 35 minutes.

Read more

Fujirebio Europe launches the RoboBlot™ instrument, a fully automated solution for INNO-LIA® Score assays

Gent, Belgium - January 18, 2022: Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the automated processing of the widely used INNO-LIA Score assays. The instrument is manufactured by Bee Robotics Ltd. and distributed by Fujirebio Europe. The system’s pre-programmed test protocols provide start-to-finish automation of strip-based INNO-LIA Score assays, from sample addition, over strip processing, image capture, to result interpretation and where applicable laboratory information system (LIS) communication.

Read more

Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2

Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology biomarkers NPTX2 and sTREM2 on the well-established INNOTEST platform. These are the first official product launches after the collaboration agreement announced in September 2020 between Fujirebio Europe and ADx NeuroSciences.

Read more

Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution

H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform. pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimer’s disease (AD). The ADDF Diagnostics Accelerator initiative is part of a collaboration with Gates Ventures and other philanthropic partners.

Read more

Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva

Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal Oropharyngeal) Assay, a molecular CE-IVD assay from its partner Atila Biosystems, Inc. The test is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs and saliva specimen. It is an isothermal assay based on Atila’s proprietary technologies.

Read more

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.